Clinical Trial Update: Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) [Phase 1]

View source ↗

Summary

Phase 1 single-dose study of Tulisokibart (MK-7240) in healthy Chinese participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Tulisokibart

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colitis, Ulcerative | Phase 1 | Status: COMPLETED